News

Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?

A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.

News

Roswell Park Experts to Showcase Groundbreaking Hematology Research at 66th ASH Annual Meeting

Roswell Park Comprehensive Cancer Center experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology ...

Video

Advances in Ovarian Cancer Treatment Show Promise for Longer Response, Survival Rates

While it remains the leading cause of death among patients with gynecologic cancers, new treatments are offering patients better outcomes and better quality of life.

Video

Graft Versus Host Disease No Longer Poses High Risk to Transplant Patients

Graft versus host disease (GVHD) used to present such a risk to transplant patients, an estimate 10-15% of patients would develop a fatal case of it.

News

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma

Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.

News

Inherited Changes in BRCA Genes Linked to Increased Risk of Multiple Myeloma

While multiple myeloma affects mostly older adults — 95% are over 50 Kenan Onel, MD, and his colleagues discovered that patients whose BRCA genes contained PGVs, which dramatically increase cancer risk, were more likely to be diagnosed ...